Tesamorelin and visceral fat: what the evidence shows

Body composition is about more than the number on a scale. Visceral fat is stored deep in the abdomen around internal organs. Tesamorelin is a prescription peptide that acts like growth hormone-releasing hormone, prompting the body to release more of its own growth hormone and influencing fat metabolism.

In two 26-week clinical trials involving adults with HIV-associated lipodystrophy, average visceral fat declined about 14% to 18% with tesamorelin, while average body weight changed little. These results apply to the people studied; they do not show that tesamorelin works as a general weight-loss treatment or produces the same results in other groups. A randomized clinical trial and the FDA prescribing information describe this evidence.

The FDA-approved use is specific: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Tesamorelin is not approved for general weight-loss management. Use for other purposes is off-label, and evidence in those settings is less established. The FDA label also states that long-term cardiovascular safety has not been established.

Tesamorelin can raise IGF-1 and affect blood sugar, so treatment involves clinical follow-up. Possible side effects include fluid retention, joint discomfort, and injection-site reactions; active cancer, pregnancy, and certain pituitary conditions are important reasons it may not be appropriate. If you’re exploring peptide therapy or body-composition care, learn about our lifestyle medicine services and schedule a visit to discuss options that fit your health history and goals.